Patents by Inventor Laurence Elias

Laurence Elias has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20180015091
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: July 26, 2017
    Publication date: January 18, 2018
    Inventors: JOSEPH J. BUGGY, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Use of inhibitors of bruton'S tyrosine kinase (BTK)
    Patent number: 9814721
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: November 14, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Use of inhibitors of bruton's tyrosine kinase (Btk)
    Patent number: 9801883
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: October 31, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Use of inhibitors of bruton's tyrosine kinase (BTK)
    Patent number: 9801881
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: November 26, 2013
    Date of Patent: October 31, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
    Patent number: 9795605
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Grant
    Filed: July 7, 2015
    Date of Patent: October 24, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Joseph J. Buggy, Laurence Elias
  • Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
    Publication number: 20170298421
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Application
    Filed: February 28, 2017
    Publication date: October 19, 2017
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20170266186
    Abstract: Methods are provided for treating a hematologic cancer comprising administering an anticancer agent to a subject identified as having an increased mobilization of a subpopulation of lymphocytes from a malignancy following administration of an irreversible Btk inhibitor. Methods also are provided for identification of subjects for treatment and the analysis of cells mobilized from a hematologic malignancy following administration of an irreversible Btk inhibitor.
    Type: Application
    Filed: December 29, 2016
    Publication date: September 21, 2017
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Methods for the treatment of HER2 amplified cancer
    Patent number: 9724349
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Grant
    Filed: June 30, 2016
    Date of Patent: August 8, 2017
    Assignee: Pharmacyclics LLC
    Inventors: Jun Chen, Joseph J. Buggy, Laurence Elias
  • Methods for the Treatment of HER2 Amplified Cancer
    Publication number: 20170151243
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Application
    Filed: June 30, 2016
    Publication date: June 1, 2017
    Inventors: Jun Chen, Joseph J. Buggy, Laurence Elias
  • Method for identification of sensitivity of a patient to telomerase inhibition therapy
    Patent number: 9617583
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: April 11, 2017
    Assignee: Geron Corporation
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20170035762
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: March 10, 2016
    Publication date: February 9, 2017
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
    Publication number: 20160324859
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: March 10, 2016
    Publication date: November 10, 2016
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Methods for the treatment of HER2 amplified cancer
    Patent number: 9415050
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Grant
    Filed: August 12, 2014
    Date of Patent: August 16, 2016
    Assignee: Pharmacyclics LLC
    Inventors: Jun Chen, Joseph J. Buggy, Laurence Elias
  • Use of Inhibitors of Bruton's Tyrosine Kinase (BTK)
    Publication number: 20160175312
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: February 26, 2016
    Publication date: June 23, 2016
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • INHIBITORS OF BRUTON'S TYROSINE KINASE FOR THE TREATMENT OF SOLID TUMORS
    Publication number: 20160000792
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Application
    Filed: July 7, 2015
    Publication date: January 7, 2016
    Inventors: Joseph J. BUGGY, Laurence ELIAS
  • Use of inhibitors of Bruton's tyrosine kinase (Btk)
    Patent number: 9125889
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: September 8, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Inhibitors of Bruton'S tyrosine kinase for the treatment of solid tumors
    Patent number: 9107924
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: August 18, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Joseph J. Buggy, Laurence Elias
  • Method for Identification of Sensitivity of a Patient to Telomerase Inhibition Therapy
    Publication number: 20150152488
    Abstract: The invention provides methods for determining the susceptibility of cancer patients to developing adverse reactions if treated with a telomerase inhibitor drug by measurement of telomere length in appropriate cells of the patient prior to initiation of the telomerase inhibitor treatment.
    Type: Application
    Filed: October 2, 2014
    Publication date: June 4, 2015
    Inventors: Calvin B. Harley, Laurence Elias, Jennifer Smith, Mark J. Ratain, Fabio Benedetti
  • Use of inhibitors of Bruton's tyrosine kinase (Btk)
    Patent number: 8999999
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: April 7, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • METHODS FOR THE TREATMENT OF HER2 AMPLIFIED CANCER
    Publication number: 20150044217
    Abstract: Described herein are methods and compositions for treating HER2-amplified cancer. The methods include administering to an individual in need thereof ibrutinib.
    Type: Application
    Filed: August 12, 2014
    Publication date: February 12, 2015
    Inventors: Jun CHEN, Joseph J. BUGGY, Laurence ELIAS